Our core team brings together over a decade of expertise in mRNA, LNP, and biologics development.They played a key role in industrializing China’s first wave of COVID-19 mRNA vaccines and have since advanced numerous programs—including mRNA protein replacement therapies, gene editing, in vivo CAR, and cancer vaccines—into global clinical stages.The team’s extensive experience in novel lipid nanoparticle development, scale-up, and application helps partners overcome critical delivery challenges.

Putting Customer First, we provide early-stage support in molecular design and delivery optimization to enhance sequence stability and translation efficiency. Our GMP manufacturing base operates in strict compliance with FDA, EMA, and NMPA regulations and houses a full suite of capabilities: plasmid DNA production, mRNA drug substance (DS) manufacturing, LNP encapsulation, lyophilization, and drug product (DP) fill-finish. We also support joint regulatory filings across China, the U.S., and Europe.

By bridging industrial gaps with proven manufacturing prowess and fostering synergy through an open platform, we continuously lower the barriers to nucleic acid drug development. Our goal is clear: to enable global partners to deliver innovative therapies to patients faster.